Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
GW Pharmaceuticals Ltd
GW has shown in phase II and III studies that Sativex has analgesic properties that are effective in relieving neuropathic pain. These studies suggested that Sativex is well tolerated and may also improve sleep and quality of life. GW is conducting this study to further demonstrate these effects.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Any disease sub-type of MS of at least two years duration
Central neuropathic pain (CNP) of at least three months and expected to remain stable for the study duration
Moderate CNP defined by NRS pain score at baseline sum to at least 24
Subject established on or previously tried and failed analgesic therapy for CNP
If receiving disease modifying medications, stable dose for 3 months and maintained for study duration
You may not be if
Subjects whose identified pain is likely to be nociceptive, musculoskeletal (including spasms) peripheral neuropathic or psychogenic in origin, or due to trigeminal neuralgia.
Other non central neuropathic pain of a severity which is likely to interfere with the patients assessment of CNP
medical history suggests subject is likely to relapse/remit during course of study
history of schizophrenia (including family history), other psychotic illness, severe personality disorder or other significant psychiatric disorder other than depression associated with MS
known or suspected history of alcohol abuse, epilepsy or recurrent seizures or hypersensitivity to cannabinoids
travel outside of the country of residence planned during the study
significant cardiac, renal or hepatic impairment
subjects with current recreational cannabis, medicinal cannabis or synthetic cannabinoid based medications within 3 months prior to study entry and unwilling to abstain for the duration of the study
Clareo Health | Sativex Versus Placebo When Added to Existing Treatment for Central Neuropathic Pain in MS
